KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $11.6 million.

  • TherapeuticsMD's Shares Outstanding (Weighted Average) rose 36.42% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 36.42%. This contributed to the annual value of $11532.0 for FY2024, which is 1044.92% up from last year.
  • As of Q3 2025, TherapeuticsMD's Shares Outstanding (Weighted Average) stood at $11.6 million, which was up 36.42% from $11.6 million recorded in Q2 2025.
  • TherapeuticsMD's 5-year Shares Outstanding (Weighted Average) high stood at $422.2 million for Q3 2021, and its period low was $10441.0 during Q4 2023.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $72.2 million, with a median of $11.1 million in 2023.
  • Per our database at Business Quant, TherapeuticsMD's Shares Outstanding (Weighted Average) soared by 5490.47% in 2021 and then crashed by 9988.43% in 2023.
  • Quarter analysis of 5 years shows TherapeuticsMD's Shares Outstanding (Weighted Average) stood at $422.2 million in 2021, then crashed by 97.86% to $9.0 million in 2022, then tumbled by 99.88% to $10441.0 in 2023, then rose by 10.45% to $11532.0 in 2024, then soared by 100264.2% to $11.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $11.6 million in Q3 2025, compared to $11.6 million in Q2 2025 and $11.6 million in Q1 2025.